Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease

Biomedicine and Pharmacotherapy

Volumn 53, Issue 3, 1999, Pages 131-140

  Brownell, A L ^a,b   Jenkins, B G ^a   Isacson, O ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Dopamine transporters; L DOPA; MPTP; MRS; Parkinson's disease; PET

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CHOLINE; CREATINE; DOPAMINE; DOPAMINE TRANSPORTER; NEUROTRANSMITTER;

AGED; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; GLIA; HUMAN; MALE; MATHEMATICAL MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL;

EID: 0033117043     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80078-X     Document Type: Article

References (82)

1. 1 Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, et al. Complementary PET studies of striatal neuronal function in the different diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997 ; 120 : 2187.
2. 18F-Methylspiroperidol: the radioligand of choice for PETT studies of the dopamine receptor in human brain. Life Sci 1985 ; 36 : 1359.
3. 3 Bailey DL, Young H, Bloomfield PM, Meikle SR, Glass D, Myers MJ, et al. ART - a continuously rotating PET camera: performance characteristics, initial studies, and installation considerations in a nuclear medicine department. Eur J Nucl Med 1997 ; 24 : 6.
4. 4 Benabid AL, Pollak P, Gao D, Hoffman D, Limousin P, Gay E. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996 ; 84 : 203.
5. 5 Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Rese 1997 ; 766 : 107.
6. 6 Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophys 1994 ; 72 : 507.
7. 7 Booij J, Busemann Sokole E, Stabin MG, Janssen AGM, de Bruin K, van Royen AE. Human biodistribution and dosimetry of (123I)FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998 ; 25 : 24.
8. 8 Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nature Med 1998 ; 4 : 1308.
9. 9 Brownell AL, Livni E, Galpern W, Isacson O. PET imaging of dopamine terminals in a rat transplant model of Parkinson disease. Ann Neurol 1998 ; 43 : 387.
10. 10 Brownell AL, Elmaleh DR, Meltzer P, Shoup TM, Brownell GL, Fischman AJ, et al. Cocaine congeners as PET imaging probes for dopamine terminals in normal and MPTP induced parkinsonism in nonhuman primate brain. J Nucl Med 1996 ; 37 : 1186.
11. 11 Brownell GL, Burnham CA, Stearns CW, Chesler DA, Brownell AL, Palmer M. Development in high-resolution positron emission tomography at MGH. Int J Imig Systems and Technol 1989 ; 1 : 207.
12. 12 Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983 ; 80 : 4546.
13. 13 Chesler DA. In: Freedman GS, ed. Tomographic Imaging in Nuclear Medicine. New York: The Society of Nuclear Medicine; 1973. p. 176.
14. 14 Delforges J, Loc'h C, Hantraye P, Stulzaft O, Khalili-Varasteh M, Maziere M, et al. Kinetic analysis of central (76Br) bromolisuride binding to dopamine D2-receptor studies by PET. J Cer Blood Flow and Metab 1991 ; 11 : 914.
15. 15 De Michele G, Filla A, Volpe G, Gogliettino A, Ambrosio G, Campanella G, et al. Etiology of Parkinson's disease: the role of environment and heredity. In: Battistin L, et al., eds. Adv Neurol. Philadelphia: Lippincott-Raven; 1996. p. 16.
16. 16 Derenzo SE, Hueasman RH, Cahoon JL. A positron tomograph with 600 BGO crystals and 2.6 mm resolution. IEEE Trans Nucl Sci 1988 ; 35 : 659.
17. 17 di Porzio U, Daguet MC, Glowinski J, Prochiantz A. Effect of striatal cells on in vitro maturation of mesencephalic dopaminergic neurons grown in serum-free conditions. Nature 1980 ; 288 : 370.
18. 18 Doudet DJ, Chan GL, Holden JE, McGeer EG, Aigner TA, Wyatt RJ, et al. 6-[18F]Fluoro-L-DOPPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998 ; 29 : 225.
19. 19 Eberling JL, Jagust WJ, Taylor S, Bringas J, Pivirotto P, Van-Brocklin HF, et al. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. Brain Res 1998 ; 805 : 259.
20. 20 Eidelberg E, Brooks BA, Morgan WW, Walden JG, Kokemoor RH. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 1986 ; 18 : 817.
21. 21 Elsworth JD, Deutch AY, Redmond DEJ, Taylor JR, Sladek JR, Ruth RH. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated primates: biochemical changes in striatal regions. Neuroscience 1989 ; 33 : 323.
22. 22 Emond P, Farde L, Chalon S, Belzung C, Mauclaire V, Chiron JP, et al. Toxicity, mutagenicity, and behavioral effects of beta-CIT, a ligand for dopamine transporter exploration by SPECT. Nucl Med Biol 1998 ; 25 : 405.
23. 23 Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986 ; 231 : 258.
24. 24 Federico F, Simone IL, Lucivero V, Iliceto G, De Mari M, Giannini P, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov Disord 1997 ; 12 : 903.
25. 25 Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991 ; 547 : 142.
26. 26 Foster DM. SAAM II: simulation, analysis and modeling software. BMES Bull 1994 ; 18 : 19.
27. 27 Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, et al. Mapping cocaine binding sites in human and baboon in vivo. Synapse 1989 ; 4 : 371.
28. 28 Freed CR, Breezr RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 and 46 months after transplantation for Parkinson's disease. N Engl J Med 1992 ; 327 : 1549.
29. 29 Freeman TB, Olanow CW, Hauser RA, Nauert M, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995 ; 38 : 379.
30. 30 Friedman JH, Epstein M, Sanes JN, Lieberman P, Cullen K, Lindquist C, et al. Gamma knife pallidotomy in advanced Parkinson's disease. Ann Neurol 1996 ; 39 : 535.
31. 31 Frohna PA, Rothblat DS, Joyce JN, Schneider JS. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. Synapse 1995 ; 19 : 46.
32. 11C-WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol 1993 ; 34 : 423.
33. 33 Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983 ; 305 : 137.
34. 34 German DC, Manaye K, Smith WK, Woodwart DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann Neurol 1989 ; 26 : 507.
35. 35 Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre-and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997 ; 120 : 503.
36. 36 Grafton ST, Waters C, Sutton JFLM, Couldwell W. Pallidotomy increases activity of motor association cortex in parkinson's disease: a positron emission tomographic study. Ann Neurol 1995 ; 37 : 776.
37. 37 Graybiel AM, Hirsch E, Agid Y. The nigrostriatal system in Parkinson's disease. In: Advances in Neurology. New York: Raven Press; 1990. p. 17.
38. 38 Guilloteau D, Emond P, Baulieu JL, Garreau L, Frangin Y, Poucelot L, et al. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl) notropane (PE21). Nucl Med Biol 1998 ; 25 : 331.
39. 39 Guimareas AR, Schwartz P, Prakash MR, Carr CA, Berger UV, Jenkins BG, et al. Quantitative nuclear magnetic resonance spectroscopic imaging of neuronal loss in excitotoxic rat brain model. Neuroscience 1995 ; 69 : 1095.
40. 40 Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-recptor binding in PET using a simplified reference region model. Neuroimage 1997 ; 6 : 297.
41. 41 Hall EJ. In: Radiobiology for the Radiologist. Philadelphia: J.B. Lippincott Co; 1994.
42. 42 Hantraye P, Brownell AL, Elmaleh DR, Spealman RD, Wullner U, Brownell GL, et al. Dopamine fiber detection by (11C)-CFT and PET in a primate model of parkinsonism. Neuro Report 1992 ; 3 : 265.
43. 43 Hirato M, Ohye C, Takahashi A, Negishi M, Shibasaki T. Study on the function of basal ganglia and frontal cortex using depth microrecording and PET scan in relation to the outcome of pallidotomy for the treatment of rigid-akinesia-type Parkinson's disease. Stereotact Funct Neurosurg 1997 ; 69 : 86.
44. 44 Holshouser BA, Komu M, Moller HE, Zijlmans J, Kolem H, Hinshaw DB Jr, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a Multicenter pilot study. Magn Reson Med 1995 ; 33 : 589.
45. 45 Imai H, Nakamura T, Endo K, Narabayashi H. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior and histology. Brain Res 1988 ; 474 : 327.
46. 46 Jankovic J. Treatment of parkinsonian syndromes. In: Kurlan R, ed. Treatment of movement disorders. Philadelphia: Lippincott; 1995. p. 95.
47. 47 Jenkins BG, Brouillet E, Storey E, Chen YI, Schultz JB, Kirschner P, et al. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996 ; 16 : 450.
48. 48 Jordan S, Eberling JL, Bankiewicz KS, Rosenberg D, Coxson PG. 6-(18F)fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res 1997 ; 750 : 264.
49. 49 Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991 ; 9 : 43.
50. 50 Kilbourn MR. In vivo binding of (18F)GBR 13119 to the brain dopamine uptake system. Life Sci 1988 ; 42 : 1347.
51. 51 Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995 ; 332 : 1118.
52. 52 Kotian P, Abraham P, Lewin AH, Mascarella SW, Boja JW, Kuhar MJ, et al. Synthesis and ligand binding study of 3 beta-(-substituted phenyl)-2 beta-(heterocyclic) tropanes. J Med Chem 1995 ; 38 : 3451.
53. 53 Kung MP, Stevenson DA, Plossl K, Meegalla SK, Beckwith A, Essman WD, et al. (99mTc)TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997 ; 24 : 372.
54. 54 Kurlan R, Kin MH, Gash DM. The time-course and magnitude of spontaneous recovery of parkinsonism by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine to monkeys. Ann Neurol 1991 ; 29 : 677.
55. 55 Lange KW. Clinical pharmacology of dopamine agonists in Parkinson's disease. Drugs Aging 1998 ; 13 : 381.
56. 56 Langston JW, Forno LS, Rbert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984 ; 292 : 390.
57. 57 Leenders KL, Aquilonius SM, Bergstrom K, Bjurling P, Crossman AR, Eckernas SA, et al. Unilateral MPTP lesion in a rhesus monkey, effect on the striatal dopaminergic system assessed in vivo by PET using various novel tracers. Brain Res 1988 ; 445 : 61.
58. 58 Leenders KL, Salmon E, Tyrrel P, Perani D, Brooks DJ, Sagar HJ, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1991 ; 47 : 1290.
59. 59 Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D, et al. Evidence of long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994 ; 32 : 172.
60. 60 Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to (N-11C-methyl)-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990 ; 10 : 740.
61. 61 Logan J, Wolf AP, Shiue CY, Fowler, JS. Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers. J Neurochem 1987 ; 48 : 73.
62. 62 Luxen A, Perlmutter M, Bida GT, van Moffaert G, Cook JS, Satyamurthy N, et al. Remote, semiautomated production of 6-(18F)fluoro-L-dopa for human studies with PET. Appl Radiat Isotopes 1990 ; 41 : 275.
63. 63 Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD. Effects of cocaine and related drugs in nonhuman primates; I.[3H] Cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 1989; 251: 131.
64. 64 Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in post-mortem normal and Parkinson's diseased brain. Synapse 1998 ; 29 : 116.
65. 65 Maloteaux JM, Vanisberg MA, Laterre C, Javoy-Agid F, Agid Y, Ladurin PM. 3H-GBR 12935 binding to dopamine uptake sites, subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988 ; 156 : 331.
66. 66 Marsden CD. Parkinson disease. Postgrad Med J 1992 ; 68 : 538.
67. 67 Martin WR, Stoessl AJ, Adam MJ, Ammann W, Bergstrom M, Harrop R, et al. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism. Adv Neurol 1989 ; 45 : 95.
68. 68 Meltzer PC, Liang AY, Brownell AL, Elmaleh DR, Madras BK. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J Med Chem 1993 ; 36 : 855.
69. 69 Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984 ; 15 : 217.
70. 70 Mizuno Y, Hattori N, Matsumine H. Neurochemical and neurodegenerative correlates of Parkinson's disease. J Neurochem 1998 ; 71 : 893.
71. 71 Moeller JR, Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson's disease and normal aging. Brain 1997 ; 120 : 2197.
72. 72 Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology 1998 ; 51 : S13.
73. 73 Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1985 ; 5 : 584.
74. 74 Piccini P, Turjanski N, Brooks DJ. PET studies of the striatal dopaminergic system in Parkinson's disease (PD). J Neural Transm Suppl 1995 ; 45 : 123.
75. 75 Prochiantz A, di Porzio U, Kato A, Berger B, Glowinski J. In vitro maturationof mesencephalic dopaminergic neurons from mouse embryos is enhanced in presence of their striatal target cells. Proc Natl Acad Sci USA 1979 ; 76 : 5387.
76. 76 Prochiantz A, Daguet MC, Herbet A, Glowinski J. Specific stimulation of in vivo maturation of mesencephalic dopaminergic neurons by striatal membranes. Nature 1981 ; 293 : 570.
77. 77 Sadzot B, Price JC, Mayberg HS, Douglass KH, Dannals RF, Lever JR, et al. Quantification of human opiate receptor concentration using high and low specific activity [11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 1991 ; 11 : 204.
78. 78 Schapira AHV. Neurotoxicity and the mechanisms of cell death in Parkinson's disease. In: Battistin L, ed. Advances in Neurology. Philadelphia: Lippincott-Raven; 1996. p. 161.
79. 79 Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, el al. Parkinson disease in twins: an etiologic study. J Amer Med Assoc 1999 ; 281 : 341.
80. 80 Tolosa E, Marti MJ, Valldeoriola F, Molinuovo JL. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998 ; 50 : S2.
81. 11C-CFT. Exper Neurol 1994 ; 126 : 305.
82. 82 Zawada WM, Zastrow DJ, Clarkson ED, Adams FS, Bell KP, Freed CR. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res 1998 ; 786 : 96.